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Pathological Mechanisms and Clinical
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ABSTRACT
The overall pathological view of paranasal sinus inflammation in the Japanese population has profoundly
changed in recent years. Eosinophilic chronic rhinosinusitis (ECRS) is a clinical entity of intractable chronic si-
nus inflammation accompanied by numerous infiltrations of activated eosinophils in the paranasal sinus mu-
cosa andor nasal polyps. Several pathologic processes are considered to act in concert to promote the accu-
mulation of eosinophils in ECRS. They include infiltration of progenitor cells, increase in local IL-3, IL-5, IL-13,
GM-CSF and eotaxin production, and upregulation of adhesion molecules. The role of nasal allergen sensitiza-
tion and innate immunity responses in the sinus mucosa has also been proposed in the development of ECRS.
Various pathogens including TLRs ligands may trigger an abnormal immune response at the mucosal surface.
The objectives of ECRS management should focus directly on inhibition of local eosinophil infiltration. Surgical
procedures include widely opening the bony wall septum of every affected sinus and mechanical removal of
diseased mucosal lesion. The use of local andor systemic steroids, leukotriene receptor antagonists, and Th2
cytokine antagonists is recommended. Local administration of steroids is a potent treatment strategy for pre-
venting relapse of nasal polyposis and is considered to be the first-line treatment for ECRS patients.
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INTRODUCTION
Paranasal sinus infection still remains one of the most
common diseases in Japan. Chronic sinusitis is an in-
flammatory disease defined as a paranasal sinus infec-
tion that has persisted for longer than 3 months. Due
to the accumulation of considerable knowledge about
the immunopathology of the disease, the overall
pathological view of paranasal sinus infection has pro-
foundly changed and evolved in recent decades. As
has been revealed by the process of diagnosing the
disease, there is a large degree of heterogeneity in
the underlying pathophysiology and associated histo-
logical features.1-3 The categorization of chronic si-
nusitis into subtypes may have important implications
for treatment and expected long-term outcomes. At
the clinical symposium of the Annual Meeting of the
Japanese Rhinological Society held in 2006, eosino-
philic chronic rhinosinusitis (ECRS) was summarized
as an entity of intractable chronic sinus inflammation
accompanied by numerous infiltration of activated
eosinophils in the paranasal sinus mucosa andor na-
sal polyps (Table 1).
Although several theories on the causes of sinus
tissue eosinophilia have been postulated, the original
cause of eosinophil recruitment is unclear, especially
in non allergic subjects.4-6 Bronchial asthma (includ-
ing aspirin-induced asthma) is known to often be con-
current with these cases. A Th2-type profile has been
implicated as one of the dominant pathogenic proc-
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Table 1 Clinical features of ECRS in Japan
 1) Remarkable infiltration of activated eosinophils is histologicaly observed in the paranasal sinus mucosa and/or nasal polyps.
 2) Adult onset cases are etiologicaly predominant.
 3) Sinus disease tends to occur bilateraly.
 4) Existence of multiple nasal polyps and characteristic mucus secretion with high viscosity.
 5) Complication of atopic diathesis is not necessary.
 6) Patients tend to show higher eosinophil count in the peripheral blood.
 7) Persistent inflammation is more common in ethmoid sinus mucosa than in maxilary sinuses to which blockage of the ostio-
meatal complex is related.
 8) Complication of lower airway disease such as bronchial asthma is frequent.
 9) Severe manifestation of olfactory dysfunction tends to occurs in earlier stage.
10) Treatment with local/systemic steroids is efective as compared to low-dose macrolide therapy.
esses in ECRS with stimulation of the adaptive im-
mune response. In this article, in order to gain an un-
derstanding of both the basic and clinical aspects of
the disease, we attempted to assess the relative
weight and role of various factors possibly involved in
eosinophil infiltration into the sinus mucosa in ECRS
patients among the Japanese population. Several so-
cieties have already proposed recommendations and
guidelines for the management of patients with
chronic rhinosinusitis and nasal polyposis based on
evidence and expert opinion.1-3 We feel that studies in
Japanese populations may be helpful for gaining an
understanding of the pathogenic mechanisms of
ECRS.
CURRENT BASIS FOR THE CHARACTERI-
ZATION OF ECRS
The clinical significance of anatomic variants of hu-
man paranasal sinus systems causing a predisposition
to sinus diseases through blockage of the ostiomeatal
complex became a subject of controversy in the late
1990s (Fig. 1). Contrary to common belief, previous
radiological studies using CT scan only confirmed the
association between persistent chronic sinusitis, sep-
tal deviations and unusual deflexions of the uncinate
process. They failed to present a significant associa-
tion between the disease and most of the other
anatomic variants (i.e., concha bullosa, paradoxical
curve of the middle turbinate, pneumatized uncinate
process, and Haller cells).7 On the other hand, a
close correlation has been noted between systemic or
local eosinophil recruitment and the extent of sinus
disease, as evaluated by computed tomography.8 In
this study, bronchial asthma, atopic diathesis, and
age were also associated with extensive disease.
ECRS is at present characterized by unrestrained
proliferation of eosinophils that form clusters in the
mucosa, where they release toxic granules.9-12 ECRS
patients with a high percentage of activated EG2-
positive cells had higher CT scores in the ethmoidal
sinuses accompanied by severe manifestation of olfac-
tory dysfunction.11 The mechanisms by which eosino-
philic inflammation damages the epithelium and con-
tributes to recurrent acute exacerbations in the dis-
ease have not been fully elucidated. Although several
studies, including ours, have qualitatively and quanti-
tatively provided data on the histopathological fea-
tures of chronic rhinosinusitis, there are no standard
levels of tissue eosinophil density to define ECRS.13
Berger et al. previously defined sinusitis patients as
having polypoid mucosa and eosinophilia (PME) ac-
cording to a guideline based on gross microscopic as-
sessment.14 They observed a significant increase in
the number of eosinophils in the PME group (median
value of 33.5 cellsmm2) compared with in sinusitis
patients with glandular hyperplasia.
THE ROLE OF ACTIVATED EOSINOPHILS IN
ECRS PATHOLOGY
Eosinophils are considered to play a major role in the
pathogenesis of ECRS through the release of noxious
secretary granules.10,11,15,16 They release major basic
protein, eosinophil-derived neurotoxin, eicosanoids,
and various cytokines. The eosinophils histologically
infiltrate into the epithelium out to the sinus cavity
through the thickened basement membrane. Disrup-
tion of mucociliary clearance systems caused by the
continuous eosinophilic inflammation eventually re-
sult in impaired immune capabilities and possible in-
fectious damage to the host.17 Several pathologic
processes are considered to act in concert to promote
the accumulation of eosinophils in ECRS.1 They in-
clude infiltration of CD34+ eosinophil progenitor
cells, increase in the local survival and activation of
eosinophils, which is dependent on local IL-3, IL-5, IL-
13 and GM-CSF production, upregulation of endothe-
lial VCAM-1 and P-selectin, and production of C-C
chemokines in epithelial cells and fibroblasts. En-
hanced production of eotaxin-1, -2, and -3 by tissue
eosinophils in Japanese ECRS patients has recently
been reported, indicating the recruitment of eosino-
phils into the tissue by a self-amplifying process.18
There seem to be inter-racial differences in the im-
munopathologic features of chronic rhinosinusitis, in-
dicating that distinct mechanisms may underlie the
pathogenesis of nasal polyps between different ethnic
Management of ECRS in Japan
Allergology International Vol 59, No3, 2010 www.jsaweb.jp 249
Major breakthrough in the treatment of rhinosinusitis in 1980s
1) Low-dose macrolides therapy as conservative treatment
2) Endoscopic sinus surgery as surgical approaches
From 1980s
Infectious (purulent) type: mainly caused by 
anatomic variants of lateral nasal walls and block-
age of the ostiomeatal complex. 
maxillary sinus dominant
infiltration of neutrophils 
In the late 1990s
Eosinophilic rhinosinusitis (ECRS): irritability of 
the sinus mucosa themselves caused by persis-
tent and extensive chronic inflammation.
ethmoid cells dominant
infiltration of eosinophils
frequent association with lower airway disease 
Fig. 1 Changes of pathohistological backgrounds and clinical characteristics of par
anasal sinus infection.
groups.19 Kim et al. found that eosinophilic nasal
polyposis accounted for only 33.3% of the 30 samples
obtained from a Korean population.20 Cao et al. re-
cently investigated the immunopathologic profiles of
chronic rhinosinusitis with nasal polyps (CRSwNP)
and without nasal polyps (CRSsNP) in a nonwhite
(adult Chinese) population.19 More than half (53.6%)
of the CRSwNP patients presented with non-
eosinophilic inflammation. The authors observed im-
paired regulatory T cell function and enhanced TH1
TH2TH17 responses in both groups. CRSsNP was
confirmed to be a predominant TH1 milieu, whereas
TH2-skewed inflammation with predominant TH17
reactions was demonstrated only in eosinophilic
CRSwNP, but not in non-eosinophilic CRSwNP. TH
17, a newly defined T-cell lineage, is known to be
deeply involved in the development of autoimmunity
and allergy. TH17 cells have been shown to upregu-
late TH2 cell-mediated eosinophilic airway inflamma-
tion.21
THE IMPLICATION OF ATOPIC STATUS
AND TH1-TH2 BALANCE
There are documented allergic and immunologic fac-
tors associated with the development of ECRS. Sev-
eral reports have intensively debated the role of nasal
allergen sensitization in the development of ECRS in
accordance with the increased incidence of an atopic
population in recent years.22-25 A role of IgE specific
for enterotoxins from Staphylococcus aureus, which
act as superantigens resulting in a multiclonal stimu-
lation of T and B lymphocytes, has also been pro-
posed in the pathogenesis of ECRS.26 Allergic status
is considered a disorder of the entire respiratory tract
rather than limited to a specific target organ. In this
sense, the pathological features of chronic sinusitis in
allergic subjects can be considered dependent on the
effects of Th2 cytokines.27 However, the original
cause of eosinophil recruitment in ECRS remains
controversial, and several authors have claimed that
atopic status does not affect eosinophil infiltration in
the disease.4,28 It has been reported that neither total
IgE concentrations nor ECP, IL-4, or IL-5 concentra-
tions in eosinophilic nasal polyps are different in
atopic versus nonatopic subjects, indicating a discor-
dance between systemic allergic phenotype and local
inflammatory mechanisms.1 Jankovski et al. exam-
ined the degree of eosinophil infiltration in a series of
263 adult patients with nasal polyposis.4 The number
of eosinophils was increased in patients with asthma,
although atopic patients did not have more eosino-
phils. Driscoll et al. also found the presence of signifi-
cantly more CD4+ cells in the sinus mucosa of sinusi-
tis patients than in the normal sphenoid sinus tissue,
a finding that was not related to allergic status.29 IFN-
γ is a well-known Th1 cytokine and its production is
depressed in CD4-positive cells from atopic subjects.
Jyonouchi et al. analyzed the production of proinflam-
matory cytokines by sinus lavage cells and proposed
that distinguished subsets of sinusitis patients with-
out nasal polyposis in Japan existed on the basis of lo-
cal IFN-γ production.30
Despite the bias toward the Th2 profile, many stud-
ies have demonstrated a mixed profile of Th1 and
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Th2 cytokines in ECRS.17 We performed immunohis-
tological analysis of paranasal sinus mucosa in Japa-
nese sinusitis patients (n = 132).13 Interestingly, the
overall distribution of eosinophil density in all pa-
tients showed a combination of two different stan-
dardized shapes, indicating the coexistence of two
different subgroups in the sinusitis pathology.14 Local
expression of a panel of cytokine mRNA and the dis-
tribution of CD4-, CXCR3-, and CCR4-positive cell
subsets were quantitatively analyzed. Cells express-
ing CXCR3 and CCR5 have been associated with the
Th1 cytokine profile, whereas CCR3, CCR4, and CCR
8 have been associated with the Th2 phenotype.31,32
The ECRS group showed similar cytokine profiles
with high expression levels for GM-CSF, IL-5, and eo-
taxin mRNA. The total number of CD4+ cells and the
density of CCR4-positive CD4+ cells was significantly
higher in this group, irrespective of the presence of
AR. These findings point toward separate pathoge-
netic pathways in ECRS that induce prolonged inflam-
matory responses and interfere with normal mucocili-
ary clearance.
POSSIBLE FACTORS RESPONSIBLE FOR
EOSINOPHIL RECRUITMENT
The exact reason for high eosinophil infiltration ac-
companied with a shift to a more type 2-dominated re-
sponse in ECRS patients is still unclear. However,
more than one mechanism seems to contribute to the
responses.16 Terada et al. mentioned that a hypoxic
state in paranasal sinuses activated endothelial cells
and fibroblasts to release inflammatory mediators,
leading to promotion of the adherence of inflamma-
tory cells to the endothelium. These include proin-
flammatory cytokines such as TNF-α and IFN-γ, as
well as Th2 cytokines, including IL-4 and IL-13, even
in non atopic subjects.33
Recently, the role of innate immunity in the parana-
sal sinuses has been proposed.34 It is well known that
airway epithelial cells not only play an important role
as the first line of immune defense, but also partici-
pate in adaptive and innate immune systems to main-
tain homeostasis and coordinate host defense.17,35,36
Paranasal sinus epithelial cells can serve as antigen-
presenting cells and amplify the inflammatory re-
sponse at the local tissue level through an innate im-
munity. Airborne fungi, staphylococcal superanti-
gens, bacterial biofilms, and viral infections have all
been found to be potential triggers.
We previously observed constitutive activation of
nuclear factor-kappa B (NF-κB), a transcription factor
deeply implicated in the regulation of various inflam-
matory cytokines, in the nasal polyp epithelium.37
NF-κB is a representative transcription factor that
deals with the gene expression of several molecules
related to various inflammatory states.38 Various
proinflammatory cytokines, chemokines, adhesion
molecules, and inducible enzymes are activated
through the NF-κB pathway. A close correlation was
found to exist between the degree of NF-κB activa-
tion and the levels of IL-8, IL-16, and eotaxin mRNA
expression. We also found that the expression of NF-
κB p50 and p65 subunits in cultured human paranasal
sinus epithelial cells was upregulated in allergic pa-
tients compared to non-AR patients.39 The increased
NF-κB activity in the structural cells can thus be con-
sidered to reflect hypersensitivity to external stimuli,
and to in part be responsible for eosinophil recruit-
ment (Fig. 2).40
Several authors have demonstrated the signifi-
cance of the innate immune response induced by toll-
like receptors (TLRs) in the human paranasal sinus
mucosa. Toll-like receptors are now recognized as be-
ing part of the innate immune system in the human
airway.41,42 The expression of TLRs in the paranasal
sinus mucosa is thought to be dependent on the de-
gree of each inflammation state and different from
that in the nasal cavity.34 In the nasal cavity, where
microbial interaction is frequent, there is likely to be
negative regulation of TLR activation and develop-
ment of tolerance to normal upper flora. TLR1 to TLR
10 are expressed in sinus tissue and studies by real-
time PCR suggest differences in the level of expres-
sion of TLRs in chronic rhinosinusitis as compared to
normal controls.17 Among them, TLR2 and TLR4
have been identified as signaling receptors activated
by bacterial cell wall components. Dong et al. re-
ported that TLR2 and TLR4 mRNA were significantly
up-regulated in human nasal epithelial cells of the in-
ferior turbinate under infectious conditions as meas-
ured by in situ hybridization.41 It is, therefore, likely
that pathogens, including TLRs ligands, may trigger
an abnormal immune response at the mucosal sur-
face.
We found that the NF-κB p50 activity levels, as
measured using the Trans AM assayTM, increased af-
ter stimulation with lipopolysaccharide (LPS) and
peptidoglycan (PGN) in a dose-dependent manner.43
TLRs are known to activate the NF-κB pathway
through MyD88, an IL-1 receptor-associated kinase,
and TNF-associated factor-6. The stimulatory effects
were significantly suppressed by pretreatment with
dexamethasone (DEX). In addition, uniform expres-
sion of the GR protein in cultured cells was identified
under all conditions and GR depletion from the cyto-
plasm induced by DEX pretreatment was associated
with a corresponding increase in GR levels into the
nucleus. These results indicate that external stimula-
tion through TLRs may induce high cytokine expres-
sion and inflammatory cell migration in the paranasal
sinus mucosa.35,41,42 In addition, glucocorticoids
(GCs) not only have anti-inflammatory effects
through transcription factor inhibition, but also
modulate innate host defenses. It was reported that
the addition of DEX to a combination of TNF-α and
IFN-γ synergistically upregulated TLR2 expression in
Management of ECRS in Japan
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Fig. 2 Model of immune response in ECRS.
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the cultured airway epithelial cells.44 These multi-
functional aspects of GC in paranasal sinus epithelial
cells indicate that GCs are capable of not only anti-
inflammatory effects via transcription factor inhibi-
tion, but also enhancement of the innate host de-
fense.45
CLINICAL TREATMENT MODALITIES OF
ECRS
The phenotype of ECRS appears to affect prognosis
after surgical or medical intervention. Haruna et al.
reported that a significant increase in the eosinophil
population was histologically observed in sinusitis pa-
tients whose therapeutic efficacy with long-term
macrolide therapy was poor.46 The objectives of man-
agement of ECRS include eradicating diseased mu-
cosa and nasal polyps, eliminating subjective symp-
toms such as nasal obstruction, rhinorrhea and in-
somnia, and preventing recurrence. There are several
treatment modalities such as the use of systemic
topical steroids, antileukotrienes and surgery.3
Figure 3 illustrates the treatment strategies pro-
posed for ECRS patients directly aimed at local
eosinophil infiltration. Surgical procedures include
widely opening the bony wall septum of every af-
fected sinus and mechanical removal of diseased mu-
cosal lesion. The combination of septoplasty and sub-
mucosal inferior turbinectomy should also be consid-
ered in order to obtain easier accessibility for postsur-
gical follow-up. Medication should be focused on re-
trieval from impaired mucosal conditions caused by
ongoing eosinophilic inflammation. The use of local
andor systemic steroids, leukotriene receptor an-
tagonists, and Th2 cytokine antagonists is recom-
mended. Postsurgical local treatment on an outpa-
tient basis such as nasal douching and nebulizer ther-
apy is also important. In case of relapse of nasal pol-
yps and deterioration of the mucosal condition trig-
gered by acute respiratory infection, prompt interven-
tion is necessary to avoid a noxious autocrine cycle of
eosinophilic inflammation.
LEUKOTRIENE RECEPTOR ANTAGONISTS
Leukotrienes are derivatives of arachidonic acid and
induce a wide range of physiological reactions includ-
ing bronchoconstriction, vasodilation, an increase in
vascular permeability, eosinophil chemotaxis and mu-
cus secretion. Several findings indicate that increased
levels of CysLT receptors in persons with ECRS in-
tensify eosinophilic inflammation in paranasal mu-
cosa.47-49 ECRS patients accompanied by aspirin intol-
erance asthma (AIA) are known to have greater cys-
teinyl leukotriene (CysLT) production.47 In the AIA
patients, the absolute number of cells expressing
CysLT1 receptors was reported to be significantly
higher as compared to that in non-AIA patients,
whereas the percentage of CD45+ leukocytes ex-
pressing LTB4 receptors showed no difference.48 In
humans, mast cells, neutrophils, eosinophils, and
macrophages positively express CysLT1 receptors,49
indicating that autocrine and paracrine activation may
occur after stimulation by the appropriate inflamma-
tory signaling. Ragab et al. evaluated the efficiency of
montelukast in patients with nasal polyps by nasal en-
Takeno S et al.
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Fig. 3 Curent treatment strategies for ECRS.
Medical treatment effective for sinusitis caused by OMC disease
= low-dose macrolides and mucolytic agents
Alternative treatment strategies directly aimed at local eosinophil infiltration
1) Surgical procedures (ESS)
Widely open bony septum of every sinuse and mechanically remove diseased mu-
cosal area. Combination of septoplasty and submucosal inferior turbinectomy 
should be considered to obtain easier accessibility for postsurgical follow-up.
2) Medication
Impairment of immune capabilities and normal clearance systems caused by ongo-
ing eosinophilic inflammation should be considered.
local and/or systemic steroids
leukotriene receptor antagonists, Th2 cytokine antagonists
3) Postsurgical local treatment on outpatient basis
Importance of continuous local treatment (nasal douching, nebulizer etc.).
Prompt intervention against relapse of nasal polyps and deterioration of mucosal 
condition. Avoidance of  noxious autocrine cycle of eosinophilic inflammation.
doscopy, acoustic rhinometry, and subjective symp-
toms. Clinical improvement in the patients occurred
in 64% of aspirin tolerant patients and in 50% of aspirin
sensitive patients.50 The beneficial efficacy of mon-
telukast combined with short-term steroid therapy in
nasal polyposis has also been reported.51
GLUCOCORTICOIDS
Glucocorticoids are known to have potent anti-
inflammatory and anti-allergic effects based on their
ability to regulate transcription factors that initiate
gene activation of various inflammatory cytokines, ad-
hesion molecules, and inflammatory mediators.52-54
Glucocorticoid receptors (GRs) are widely expressed
in various kinds of cells including epithelial cells and
infiltrating cells located in the nose and paranasal si-
nuses. Therefore, the anti-inflammatory effect of GCs
directly impacts the paranasal sinus mucosa. Rela-
tively, higher levels of GR expression in ECRS pa-
tients suggests that glucocorticoids may exert a
greater influence on eosinophils, thereby making
them more effective in the treatment of the disease. A
relationship between GR isoform patterns and the
clinical effectiveness of steroid treatment has been re-
ported in human nasal polyps.55
Resistance to steroid treatment is one of the major
causes of clinical failure in the treatment of ECRS and
thus an interesting topic of study.56,57 Two isoforms
of the human GR were identiﬁed in 1985 and termed
GRalpha (GRα) and GRbeta (GRβ), which originate
from alternative splicing of the GR primary transcript.
When overexpressed in various cell types, GRβ acts
as a dominant-negative inhibitor of GRα for the re-
pression of AP-1 and NF-κB activities.58 The overex-
pression of GRβ has been shown to contribute to dis-
eases associated with glucocorticoid resistance or in-
sensitivity.56,57
We have examined immunohistochemical localiza-
tion of different GR isoform expression in the parana-
sal sinus mucosa in ECRS patients. GRβ expression
was mainly found to be positive in inflammatory cells
that were scattered in the submucosal layer. It has
been reported that nearly all of the GRβ-positive in-
flammatory cells were accounted for by CD3-positive
T lymphocytes, activated eosinophils, and CD68-
positive macrophages.57 The finding tended to be
more predominant in the ethmoid sinus mucosa than
in the maxillary sinus mucosa in the same subject.
Various proinﬂammatory cytokines have been re-
ported to induce an increased expression of GRβ in
vitro. The increased expression of GRβ in the inflam-
matory cells from ECRS patients could be in part sec-
ondary to the effect of high levels of those proinﬂam-
matory cytokines in a paracrine fashion.59 In addition,
a higher expression of GRβ in certain poor respond-
ers may also represent a secondary drug resistance
mechanism in the disease.
Local administration of glucocorticoids is clinically
considered to be a potent treatment strategy to pre-
vent relapse of nasal polyposis in ECRS patients. The
beneficial effects of various preparations of topical
corticosteroids, such as betamethasone sodium phos-
phate, beclomethasone dipropionate, fluticasone
propionate, mometasone furoate, and budesonide na-
sal sprays, have been demonstrated in several ran-
domized, placebo-controlled trials.60,61 With respect
to bioavailability, systemic absorption is negligible
with mometasone and fluticasone but high for be-
tamethasone and dexamethasone, which should be
used in the short-term.
Postoperative administration of intranasal corti-
costeroids has also been demonstrated to reduce na-
sal polyp recurrence and deterioration of the mucosal
condition after endoscopic sinus surgery. However,
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Before surgery
(Rt nasal cavity)
At the end of surgery
(BDP powder treatment)
a
b
Fig. 4 (a) A representative case of ECRS patients who had received topical use of BDP dry powder for 
the post-surgical treatment. (b) Postoperative assessment of endoscopic appearance of the nasal cavity 
in sinusitis patients after the ESS in Hiroshima University Hospital (modified from Takeno et al., 2007). 
The total endoscopic grading score is calculated on the basis of the local grading scale for the maxilary 
and ethmoid sinuses on both sides.
total endoscopic grading score
2 3 4 6
better worse
total (n = 152)
non-ECRS (n = 113)
ECRS without BDP (n = 39)
ECRS with BDP (n = 35)
*p < .05, Fisher’s exact test
64% 18% 14% 4%
4%11%17%68%
51% 21% 23% 5%
57% 34% 6% 3%
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there is no evidence for how long treatment would be
appropriate.2 We recently evaluated the clinical effec-
tiveness of the topical instillation of beclomethasone
dipropionate (BDP) dry powder onto the paranasal si-
nus mucosa after surgical intervention in ECRS pa-
tients.62 The patients were treated with 800 μg BDP
powder every two weeks using a special application
device for at least 2 months (Fig. 4a). As shown in
Figure 4b, distinct improvement in the endoscopic
appearance scores occurred in 91.4% of patients who
received BDP powder treatment. The result was bet-
ter than that obtained from the previous study in
which treatment was done with conventional therapy
(71.7%). Significant decreases in the averaged CT
scores for the paranasal sinuses were also noted. We
consider the BDP treatment to be effective for ECRS
patients through the control of the inflammatory
process that persists in the paranasal cavity.
The administration of systemic steroids is recom-
mended in the short term and preferably in combina-
tion with use of a topical nasal steroid. A recent
double-blind randomized controlled trial established
Takeno S et al.
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the clinical utility of a short course of oral prednisone
in patients with nasal polyps.63 Oral steroids used pre-
operatively in sinusitis patients with nasal polyps un-
dergoing endoscopic sinus surgery have been shown
to reduce bleeding volume and consequently improve
conditions of the surgical field, leading to a shorter
operating time.64
SURGICAL TREATMENT
The beneficial outcomes of endoscopic sinus surgery
have been well described in ECRS patients. Although
it might be difficult to compare each technique and
result from different groups, one key point is that sur-
gical procedures alone are generally not sufficient to
cure the underlying inflammatory processes of the
nasal mucosa in ECRS patients.46 As shown in Figure
3, supplementary medical treatment is usually neces-
sary to prevent recurrence of the disease. The ap-
pearance of both an intra- and postoperative low num-
ber of eosinophils seems to be an indicator of good
subjective recovery. Validation of the clinical, objec-
tive and immunological parameters that accompany
recurrence of ECRS during the post-operative course
indicate that long-term follow-up is essential for ECRS
patients. The beneficial effect of ESS has recently
been proposed to decrease eosinophil traffic into the
maxillary sinus mucosa through the reduction of en-
dothelial L-Selectin ligands.65 Matsuwaki et al. re-
ported that patients with ECRS showed a high inci-
dence of recurrence within 5 years and had a positive
predictive value of 85.7%.66
CONCLUSION
We discussed the current understanding of basic and
clinical aspects of ECRS among the Japanese popula-
tion. Eosinophil accumulation in sinus tissue can be
attributable to an autostimulatory loop of related cy-
tokines and mediators, regardless of atopic status.
The clinical efficacy of steroids in the management of
ECRS has become apparent. The beneficial outcomes
of ESS have also been described in combination with
supplementary local treatment on an outpatient basis
to prevent abrupt deterioration of the disease. Fur-
ther accumulation of a consensus regarding the clas-
sification and definition of various subtypes of the dis-
ease might be required.
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